The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer ...